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Mapping EORTC-QLQ-C30 to EQ-5D-3L in Patients with Colorectal Cancer 
Abstract (297/300) 
Aims 
The primary aim of this study was to perform a mapping of the EORTC-QLQ-C30 scores to 
EQ-5D-3L for the SIRFLOX study; a large dataset of patients with previously untreated 
liver-only or liver-dominant metastatic colorectal cancer (mCRC). A secondary aim was to 
compare the predictive validity of existing mappings from EORTC-QLQ-C30 to EQ-5D-3L 
conducted in other cancers. 
Methods and Materials 
Questionnaires (completed within 529 patients) were used in a linear mixed regression to 
model EQ-5D-3L utility values (scored using the UK tariff) as a function of the five function 
scores, nine symptom scores and the global score from the EORTC-QLQ-C30 questionnaire. 
A Tobit regression was also performed. The mean EQ-5D-3L values for the SIRFLOX trial 
were calculated and compared with predicted EQ-5D-3L values derived using published. 
Results 
The linear mixed regression model provided a satisfactory mapping between the EORTC-
QLQ-C30 and the EQ-5D-3L, whilst the Tobit model did not perform as well. When utilities 
from the SIRFLOX data were calculated with previously published mapping studies, three 
out of five studies performed well (<10% mean difference). 
Limitations 
The main limitation of the study was the lack of meaningful observations post-progression 
(67 paired observations). For this reason, we were unable to test whether the mapping holds 
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by disease stage. Additionally, although the study adds to the literature of mappings to the 
EQ-5D-3L, it is not known how results would differ using the EQ-5D-5L. 
Conclusion 
This study is the first of its kind in liver-only or liver-dominant mCRC, and mCRC in 
general. The mapping constructed showed a good fit to the data and provides practitioners 
with an additional mapping between EORTC-QLQ-C30 to EQ-5D-3L using a large dataset 
(529 patients, 707 paired observations). The study also confirmed the generalisability of 
mappings published by Proskorovsky, Kontodimopoulos and Longworth to liver-only or 
liver-dominant mCRC. 
 
Keywords 
Health-related quality of life; cost-utility, patient-reported outcomes; health state utility; 
quality of life. 
Short title 
Mapping utilities in patients with colorectal cancer. 
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Introduction 
Cost-utility analysis is practiced by many healthcare authorities, such as the National Institute 
for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) in the 
UK and the Tandvårds- & läkemedelsförmånsverket (TLV) in Sweden, and is one of the most 
commonly used forms of economic evaluation [1, 2]. This approach takes into account the 
cost, the quality and the length of life, which are combined as a cost per quality-adjusted life 
year. For this, quality of life is measured by a utility value – health states are located on this 
scale based on individuals’ preferences, which are elicited by techniques such as time trade 
off, visual analogue scale or standard gamble. 
Although many instruments can be used to measure quality of life, it is not always possible to 
generate utilities from the results [2]. Generic preference-based instruments, such as the EQ-
5D-3L, are typically used to measure quality of life in disease [3]. For many of these 
instruments, the responses can be transformed into utilities using available population tariffs 
based on these preferences. The use of condition-specific instruments in clinical trials is also 
widespread to gain insight on how an intervention affects particular symptoms of a disease. 
Such instruments are believed to be more sensitive to changes in disease symptoms, and they 
may allow label claims by the US Food and Drug Administration regarding patient-reported 
outcomes. However, population preferences are generally not available for these metrics, and 
those that are available seldom have the level of research that has been performed on generic 
instruments [2]. Owing to the lack of population preference data, it is typically not possible to 
generate utilities – a solution for this is to map onto generic measures, such as the EQ-5D-3L, 
by establishing a relationship between the two instruments using regression techniques [3].  
The EORTC-QLQ-C30 is one such condition-specific measure, being specific to cancer. As 
well as more general symptoms, such pain, it also covers symptoms that are more typically 
associated with cancers such as fatigue, gastrointestinal symptoms and financial concerns. 
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Using the Oxford mapping database [4], we identified nine mappings between the EORTC-
QLQ-C30 and the EQ-5D-3L performed across a range of cancers. Of these, five used EQ-
5D-3L with the UK tariff. Similarly Doble et al. [5] performed a systematic review, 
identifying the same nine studies, and one additional study, and applied them to a large 
Australian dataset (3560 observations) to assess predictive accuracy and external validity 
across a range of cancers. Two of the 10 studies in the work by Doble et al. [5] showed 
particularly good external validity: those by Longworth et al. [3] (which used the UK EQ-5D-
3L tariff) and Versteegh et al. [6] (which used the Dutch EQ-5D-3L tariff). In addition to the 
mappings to the EQ-5D-3L, a set of population preferences of 674 of multiple myeloma 
patients, the EORTC-8D, has been developed by Rowen et al. [7]. However, none of the 
published studies that used the UK tariff were conducted in, or included, patients with 
mCRC. The lack of existing mapping algorithms in this patient population means that 
mappings from alternative cancers must be used to derive utility values from EORTC-QLQ-
C30 in mCRC. This may lead to a potential bias of unknown magnitude and direction, as it is 
possible that the symptoms of different cancers may have different affects. 
Therefore, the objectives of this study were to perform a mapping of the EORTC-QLQ-C30 
scores to EQ-5D-3L in patients with liver-only or liver-dominant mCRC and to compare the 
predictive validity of existing methods of utility generation from the EORTC-QLQ-C30 score 
in this patient population. 
Methods  
Instruments 
The EQ-5D-3L is a generic quality of life instrument that is widely used in economic 
evaluation [1]. The instrument consists of five items (mobility, self-care, usual activities, pain 
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and anxiety and depression), each of which has three levels; this results in 243 possible health 
states in which a patient can reside. 
The EORTC-QLQ-C30 is a cancer-specific quality of life instrument. It consists of 30 items 
from which five function scores, nine symptom scores and a global score can be derived 
based on the individual responses [8]. These instruments are standardised questionnaires with 
translations that are tested for linguistic and content validity. 
Data and software 
SIRFLOX was a randomised, multicentre trial designed to assess the efficacy and safety of 
adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to 
standard chemotherapy in patients with previously untreated mCRC [9]. Chemotherapy-naïve 
patients with liver metastases with or without limited extra-hepatic metastases were 
randomised to receive either mFOLFOX6 (control arm) or mFOLFOX6 plus SIRT with or 
without bevacizumab (SIRT arm). Between October 2006 and April 2013, 530 patients were 
randomised to treatment (control: 263; SIRT: 267).  
In the trial, EQ-5D-3L was completed at baseline, 3 months, 6 months, 12 months and then 
yearly. EORTC-QLQ-C30 was collected at baseline, 1 month and 12 months. There was also 
a small proportion of patients that completed the EORTC-QLQ-C30 at 3 months. Patients 
were recruited from 87 centres in Australia, Europe, Israel, New Zealand and the United 
States [9]. 
All analyses were performed in the statistical software R (version 3.2.2), using the packages 
MASS, nlme and VGAM. 
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Mapping analyses 
The methods published in the MAPs statement [10] and the work by Longworth et al. [3] 
were followed to guide selecting the appropriate model and conducting the analyses.  
A linear mixed regression was used to model EQ-5D-3L utility values as a function of the 
five function scores, nine symptom scores and the global score from the EORTC-QLQ-C30 
questionnaire. A linear mixed regression model consists of both fixed effects and random 
effects and was used to allow for multiple observations per individual, which are likely to be 
correlated. 
A Tobit regression was also performed. This model, also known as a censored regression 
model, estimates linear relationships between variables where there is either left or right 
censoring [11]. Values that are at or above a threshold take on the value of that threshold. 
This model was explored as it takes into account that the EQ-5D-3L utility values cannot be 
greater than one and is also an approach that has been used in previous mapping algorithms 
[3, 12, 13]. As with the linear mixed regression, EQ-5D-3L utility values were modelled as a 
function of the 15 scores available from the EORTC-QLQ-C30 questionnaire. 
For use in the regression analysis, observations measured from the same patient within the 
same visit were paired. Measurements without a corresponding data point in the alternative 
instrument were dropped from the analysis – as a result, no observations were used from the 
EQ-5D-3L questionnaires collected at 6 months or post 12 months, and only a fraction of 
those collected at 3 months were used. The EORTC-QLQ-C30 observations collected at 1 
month were dropped from the analysis for the same reason.  
The minimum difference considered to be clinically important for this analysis was 0.08 [14]. 
For validation of previously published algorithms, we used the sample of matching 
observations to calculate the mean of the EQ-5D-3L utility values at baseline, pre-
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progression and post-progression using all eligible mapping algorithms. Where more than one 
algorithm was available, the author’s preferred algorithm was used. Only studies where the 
UK EQ-5D-3L tariff had been used were included (five studies) to allow a comparison of 
results. EORTC-8D values were also derived from the EORTC-QLQ-C30, using the mapping 
algorithm reported by Rowen et al. [7].  
Performance of mapping algorithms 
We used statistical measures to assess the goodness of fit of the models including the mean 
absolute error (MAE), root mean squared error (RMSE) and adjusted R2. These performance 
measures are used to assess goodness of fit in the majority of mapping studies and so using 
these allows for an easy comparison to existing models. We also plotted the fitted values 
against the observed values as quantile-quantile plots to visually assess fit, as well as testing 
the fit of the model in each quartile of results. 
Results  
Our analysis included 529 patients who completed a total of 1740 EQ-5D-3L observations 
(1100 pre-progression, 108 post-progression and 456 where progression status is unreported) 
and 1241 EORTC-QLQ-C30 observations (789 pre-progression, 108 post-progression and 
344 where progression status is unreported) [9]. This is shown in Table 1. [Table 1 here] The 
intraclass correlation coefficient as a measure of the correlation within patients of the utility 
score was 0.386. 
Following the matching of observations, 707 pairs of observations were included in the 
analysis. Of these, 455 were pre-progression, 64 were post-progression and 188 observations 
had an unreported progression status. The patient demographics of this sample are described 
in Table 2. The mean EQ-5D-3L utility from these paired observations was, on the control 
arm, 0.80 at baseline, 0.81 pre-progression and 0.72 post-progression and, on the SIRT arm, 
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0.78 at baseline, 0.78 pre-progression and 0.84 post-progression (Table 3). [Table 2 and 
Table 3 here] 
The regression results for the linear mixed regression model are shown in Table 4. Four of 
the five function scores were positive and statistically significant (p<0.01), with social 
functioning being the only exception. The global score was also positive and statistically 
significant (p<0.05). As would be expected, the pain symptom score had a negative impact on 
EQ-5D-3L utility (p<0.00001), as did financial problems (p<0.01). The algorithm is a simple 
additive model. To get the utility value it can be applied to a data set by multiplying all the 
coefficients (reported in Table 4) by the corresponding EORTC-QLQ-C30 scores and adding 
the sum of these to the constant. [Table 4 here] 
The results for the Tobit model were similar to those from the linear mixed regression model 
(Table 4); the global score and all function scores, except for social functioning, were 
positive and associated with improved quality of life (p<0.01). Coefficients for pain 
(p<0.00001), financial problems (p<0.005) and appetite loss (p<0.05) also reached statistical 
significance in this model.  
Predictive performance  
The MAE for the linear mixed regression model was 0.127 and the RMSE was 0.092. These 
values were lower than those for the Tobit model (MAE=0.164, RMSE=0.121), suggesting 
that the linear mixed regression model fits the data better. The adjusted R2 for the linear 
mixed regression model was 0.646, indicating that a relatively large proportion of the 
variation was explained by the model. The adjusted R2 for the Tobit regression was 0.506, 
showing the regression to be a relatively good predictor of EQ-5D-3L utility based on 
EORTC-QLQ-C30 score (but again, worse than the linear mixed regression model). The 
residuals from the linear mixed regression model ranged from -0.6 to 0.4, with the majority at 
Page 11 of 22 
0. This was much smaller than the Tobit model where residuals ranged from -2 to 6. Data 
were ordered by utility values, from highest to lowest, and divided into quartiles. Table 5 
shows the fit to the data for each quartile. The results show that both models slightly 
underestimate utility in the less severe states and slightly overestimate utility in the more 
severe states. This is to be expected considering the nature of the EQ-5D measure. The model 
shows a good fit to the middle 50% of the data. [Table 5 here] The fit was also tested for 
when the observed utility is equal to 1 and <0.5. Where observed EQ-5D utility values equal 
1, both the linear mixed effects and the Tobit model under predicted utility (linear mixed 
effects: mean 0.90, MAE 0.10, RMSE 0.12, adjusted R2 0.49; Tobit: mean 0.91, MAE 0.09, 
RMSE 0.12, adjusted R2 0.49). The mean observed EQ-5D was 0.22 for the 56 observed 
utilities that were less than 0.5. Both the linear mixed effects and Tobit models over predicted 
these more severe health states (linear mixed effects: mean 0.55, MAE 0.32, RMSE 0.35, 
adjusted R2 0.48; Tobit: mean 0.54, MAE 0.32, RMSE 0.35, adjusted R2 0.48). 
Figure 1 shows a comparison between the fitted EQ-5D-3L estimates and the observed data 
for both models. The solid line shows the line of perfect correlation. These plots show a 
relatively good fit to the data in the linear mixed regression model, although there may be a 
tendency to overestimate utility in more severe states, with similar results seen in the Tobit 
model. The quantile-quantile plots (Figure 2) show relatively good fits over the whole 
spectrum of severity but with some departures from the predicted fit at the upper and lower 
ends of the distribution. The solid line in the figure shows the line of perfect correlation. We 
selected the linear mixed regression model as the preferred model because it was a better fit 
to the data across all measures of goodness of fit. 
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Comparison to other mapping studies and EORTC-8D 
Table 6 lists the relevant papers identified in Oxford database [4], and in the paper by Doble 
et al. [5], and shows the results for the analyses that we conducted using the five published 
algorithms between the EORTC-QLQ-C30 and EQ-5D-3L, which were scored using the UK 
value set. Mapping analyses were not performed for all studies identified, only those using 
the UK tariff. The estimated mean utility for three of the five published mappings closely 
matched the observed EQ-5D-3L utility (mean utility within 10%) [3, 15, 16], while for two 
of the mappings the mean utility did not match well [17, 18]. Of those that did not fit well, 
the study by Crott et al. (conducted in 448 patients) [17] gave a predicted utility of 0.49 using 
the SIRFLOX data – dramatically lower than the observed 0.79 mean utility (a 38% under 
prediction). McKenzie et al. (conducted in 199 patients) [18] also did not provide a good fit 
(0.70, a 14% under prediction). 
Of the algorithms that did match the data well (despite being from different disease areas), 
two underestimated [3, 16], and one over-estimated [15], the EQ-5D-3L utility. The two that 
underestimated EQ-5D-3L were used for patients with multiple myeloma. The study by 
Kontodimopoulos et al. was used for patients with gastric cancer, a disease with symptoms 
similar to those seen in mCRC. [Table 6 here] 
The utilities derived from the EORTC-8D are shown in Table 7 and show a similar pattern to 
the EQ-5D-3L values from the SIRFLOX study for all arms (see Table 3), although most 
values are approximately 0.05 higher than the equivalent EQ-5D-3L utility value. [Table 7 
here] 
Discussion 
The aim of this study was to map EORTC-QLQ-C30 values to EQ-5D-3L in patients with 
liver-only or liver-dominant mCRC, based on data collected in the SIRFLOX clinical trial. 
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Both the mixed effects and Tobit models showed a good fit to the data. Owing to the nature 
of the Tobit model, where censoring limited the utility values to fall within the bound of the 
EQ5D-3L (-0.59 to 1.00), it would be expected that the Tobit model has the better fit to the 
data. The results showed that the Tobit model provides a reasonable fit to the data, as 
demonstrated by a low RMSE and MAE and a high adjusted R2. However, the linear mixed 
regression model performed better in all measures of goodness of fit, and thus it is our 
preferred model.  
When comparing results obtained with the SIRFLOX data using algorithms from other 
mapping studies, three studies performed well and two provided poor estimates of observed 
utility. The reasons for these discrepancies are unclear, but they may be related to the disease 
areas used, the severity of patients varying between studies or simply chance. The review 
paper by Doble et al. [5] recommended the Longworth et al. algorithm [3] as providing a 
good fit to external data, and it also showed a good fit to our data (it predicted a utility of 0.75 
compared to an observed utility of 0.79). The other algorithm recommended by Doble et al. 
[5] (Versteegh et al. [6]) was not included in our analysis as it was not based on the UK EQ-
5D-3L tariff.  
Although we only have data from a single stage of disease, we did find support for the three 
algorithms that fit our data. The mapping that provided the closest fit to the observed data 
(Kontodimopoulos et al. – 0.80 versus 0.79) was conducted in gastric cancer [15], which we 
would expect to have symptoms more similar to liver-only or liver-dominant mCRC than 
other conditions used in the mappings. It should be researched further whether this was by 
chance or due to a systemic relationship between the instruments based on disease area. 
Our results are consistent with those that have been previously reported, where mapping from 
different mappings from EORTC-QLQ-C30 to EQ5D-3L can result in varied predicted 
utilities [19]. Additionally, our studies further show that mapping EORTC-QLQ-C30 to 
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EQ5D-3L tends to overestimate EQ-5D-3L utility values in the more severe health states 
[19]. Further research is required into alternative regression methods, which more accurately 
predict EQ-5D-3L utility from EORTC-QLQ-C30, particularly towards the edges of the 
distribution.  
The main limitation of the study was the lack of meaningful observations post-progression 
(67 paired observations). For this reason, we are unable to test whether the mapping holds at 
the next (or previous) stage of the disease. Although we would not expect the relationship 
between the instruments to change, due to the lack of protocol-driven visits at the same time 
points, we are not able to confirm this is the case. A second limitation is that the study was 
conducted using the EQ-5D-3L rather than the EQ5D-5L, which is now available and 
contains five levels per item rather than three. It is expected that this version is more sensitive 
to changes in quality of life and may soon be replace the three level version. A further 
limitation is that patients in the study were drawn from numerous countries and spoke 
multiple languages, and it is possible that this may have impacted on the results.  
In conclusion, this study is the first of its kind in liver-only or liver-dominant mCRC and in 
mCRC as a condition. The mapping constructed shows a good fit to the data and provides 
practitioners with an additional mapping between EORTC-QLQ-C30 and EQ-5D-3L using a 
large dataset in a previously unstudied disease area. Further research into the link between 
EORTC-QLQ-C30 and EQ-5D-3L in different datasets is needed. This should include a 
range of cancers, both in type and severity, to further assess the predictive accuracy of 
mappings and whether a generic mapping function is likely to be valid, irrespective of the site 
of disease, or whether different mappings are needed for different cancers.  
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Figure 1 Fitted versus actual EQ-5D-3L values 
 
Figure 2 Quantile-quantile plots for mapping algorithms 
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Table 1: Summary of the number of observations over time  
 
 
 Number of Observations 
 
Baseline  1 Month 3 Months  6 Months 12 Months  24 Months 36 Months On Progression  Unreported  Total  
EQ5D-3L 358 308 304 256 194 42 15 239 24 1740 
EORTC-QLQ-C30 268 221 224 186 129 30 10 154 19 1241 
Pairs 160 116 123 104 74 16 7 95 12 707 
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Table 2: Patient Demographics of the sample 
  
  
Number of Patients  529 
Number of Observations 707 
Treatment Received 
SIRT + FOLFOLX 
FOLFOX alone 
 
53% 
47% 
Received bevacizumab  50% 
Mean Age 62 
% Male  68 
WHO performance score 
0 
1 
 
68% 
32% 
Mean Tumour Burden 17.19% 
Primary Insitu 
Yes 
No 
 
43% 
57% 
Observations 
Pre-progression 
Post-progression 
Unknown 
 
90% 
7% 
3% 
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Table 3: Mean EQ-5D-3L utilities directly in the SIRFLOX trial 
Treatment 
arm 
Mean Baseline utility, 
SD (number of 
observations) 
Mean Pre-
progression, SD 
(number of 
observations) 
Mean Post-
progression, SD 
(number of 
observations) 
mFOLFOX6 
[± 
bevacizuma
b] 
0.80, 0.21 (244) 0.81, 0.21 (314) 0.72, 0.22 (29) 
SIRT + 
FOLFOX 
0.78, 0.21 (223) 0.78, 0.22 (325) 0.84, 0.19 (21) 
All patients  0.79, 0.21 (473) 0.79, 0.21 (639) 0.77, 0.21 (50) 
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Table 4: Regression results for mapping algorithms 
Predictor 
Mixed effects model Tobit model 
Coefficients SE P value Coefficients SE P value 
Constant 0.3982 0.0492 8.99E-15  0.416938 0.0489 3.67E-17 
Physical  0.0019 0.0004 <0.0001* 0.001775 0.0004 <0.0001* 
Role 0.0011 0.0003 0.0010* 0.001001 0.0003 0.0014* 
Emotional  0.0014 0.0003 <0.0001* 0.001494 0.0003 <0.0001* 
Cognitive 0.0010 0.0004 0.0058* 0.000898 0.0004 0.0122* 
Social  -0.0003 0.0003 0.3826 -0.00024 0.0003 0.4162 
Global  0.0008 0.0004 <0.0001* 0.000819 0.0004 0.0239* 
Fatigue -0.0005 0.0004 0.1541 -0.00065 0.0004 0.0993 
Nausea 0.0006 0.0004 0.1839 0.000536 0.0004 0.2294 
Pain -0.0021 0.0003 <0.0001* -0.00227 0.0003 <0.0001* 
Dyspnoea 0.0003 0.0003 0.4164 0.000192 0.0003 0.5231 
Insomnia 0.0002 0.0002 0.4542 0.000232 0.0002 0.3109 
Appetite  -0.0005 0.0003 0.0515 -0.00052 0.0003 <0.0001* 
Constipation <0.0001 0.0002 0.9981 7.20E-06 0.0002 0.9761 
Diarrhoea <0.0001 0.0003 0.8649 9.30E-05 0.0003 0.7157 
Finance  -0.0006 0.0002 0.0046* -0.0006 0.0002 0.0032* 
Performance Measures 
MAE 0.127 0.164 
RMSE 0.092 0.121 
Adjusted R2 0.646 0.506 
*Statistically Significant  
Key; SE, Standard Error; MAE, mean absolute error; RMSE, root mean squared error 
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Table 5: Goodness of fit statistics for quartiles and all data  
 
    
Quarter 
1* 
Quarter 
2 
Quarter 
3 
Quarter 
4** 
All 
data 
Mixed Effects Model 
Actual  1.00 0.89 0.76 0.52 0.79 
Predicted 0.89 0.85 0.79 0.63 0.79 
MAE 0.10 0.09 0.08 0.17 0.13 
RMSE 0.12 0.12 0.10 0.23 0.09 
Adjusted R2 0.49 0.49 0.49 0.50 0.65 
Tobit 
Actual  1.00 0.89 0.76 0.52 0.79 
Predicted 0.89 0.85 0.79 0.62 0.79 
MAE 0.09 0.09 0.08 0.17 0.16 
RMSE 0.12 0.12 0.10 0.23 0.12 
Adjusted R2 0.49 0.49 0.50 0.38 0.51 
Key: MAE; Mean absolute error, RMSE; Root mean squared error 
*25% of observations with the highest EQ5D utility values 
**25% of observations with the lowest EQ5D utility values 
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